Palisade Bio, Inc. (($PALI)) announced an update on their ongoing clinical study. Study Overview: Palisade Bio, Inc. has completed a Phase 1 ...

“These results represent a significant milestone for PALI-2108,” said JD Finley, Chief Executive Officer of Palisade Bio. “The early clinical activity, targeted delivery, dose flexibility, the ...